DelveInsight Business Research, LLP: TEPMETKO Continues to Strengthens its Position as a Leading METex14 Skipping NSCLC Therapy | DelveInsight
With increasing biomarker-driven cancer treatments, TEPMETKO benefits from growing adoption in precision oncology. Competition from other MET inhibitors like TABRECTA (capmatinib) exists, but ...
TEPMETKO Continues to Strengthens its Position as a Leading METex14 Skipping NSCLC Therapy | DelveInsight
DelveInsight's "TEPMETKO Market Size, Forecast, and Market Insight Report" highlights the details around TEPMETKO, a kinase ...
Immunocore reports fourth quarter and full year 2024 financial results and provides a business update
Q4 net sales of $84.1 million and $310.0 million for full year 2024; continued growth expected in 2025Executing on ...